Proteinuria and Renal Perfusion in Renal Transplant Recipients
Launched by UNIVERSITY OF ERLANGEN-NÜRNBERG MEDICAL SCHOOL · Sep 20, 2023
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the relationship between protein levels in urine (proteinuria) and blood flow in the kidneys of patients who are about to receive a kidney transplant. Researchers want to understand how proteinuria changes after the transplant and how it might be linked to heart health, since people with kidney transplants have a higher risk of heart disease. The goal is to find out if the blood flow in the native kidneys (the kidneys that were already in the patient) affects protein levels after the transplant and to see if there are any changes in the small blood vessels in the eye related to this proteinuria.
To participate in this study, patients must be between 18 and 75 years old and have been approved for a living donor kidney transplant. They should also have some urine output before the transplant. Participants will visit the Clinical Research Center four times over 5 to 12 months. This research is important because understanding these connections may help improve the care of kidney transplant patients and reduce their risk of heart problems.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age of 18 - 75 years
- • Male and Female patients
- • Patients evaluated and accepted for living donor kidney transplantation with residual urine output of at least 500 ml/24 hours
- • Informed consent has to be given in written form
- Exclusion Criteria:
- • Patients in unstable conditions due to any kind of serious disease, that infers with the conduction of the trial
- • active Drug or alcohol abuse
- • Pregnant and breast-feeding patients
- • Body mass index \> 35 kg/m²
- • Subjects who do not give written consent, that pseudonymous data will be transferred in line with the duty of documentation and the duty of notification according to § 12 and § 13 GCP-V
- • Implanted pacemakers or defibrillators
- • Other implanted metallic devices, which are not MRI compatible
- • Claustrophobia
- • Any other relevant clinical contraindication of MRI examination
About University Of Erlangen Nürnberg Medical School
The University of Erlangen-Nürnberg Medical School is a prestigious institution dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. Renowned for its interdisciplinary approach, the medical school fosters collaboration among experts in various fields, enabling the development of cutting-edge therapies and treatment protocols. With a commitment to ethical standards and patient safety, the institution actively contributes to the global medical community by conducting rigorous clinical studies aimed at enhancing the understanding and management of diverse health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Erlangen, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported